Spectrum: Autism Research News

This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.

This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.

Despite grave side effects, it’s vital to keep developing treatments for rare genetic forms of childhood epilepsy, says West, president of the KCNT1 Epilepsy Foundation and father of a son with the condition.

Most children with the condition, however, gain communication and social abilities over time.

A dozen papers have been retracted so far, and six more are planned.

But the field needs to move on from cross-sectional studies to gain insights into the causes and consequences of the association, experts say.

The paper was published in a journal that shut down after being overrun by paper mills.

The most prevalent conditions include obesity, neurological disorders, anxiety and attention-deficit/hyperactivity disorder.

This month’s Going on Trial newsletter explores how organ-on-a-chip models could smooth the transition from preclinical to clinical trials, among other drug development news.

A total of 17 studies have already been retracted or are slated for retraction over issues with participant consent.